抗性高血压的阿尔多合成酶抑制剂:药理学见解 - 系统性审查
Arrigo F G Cicero1,2, Giuliano Tocci3, Ashot Avagimyan4
1Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Sant' Orsola-Malpighi Hospital - University of Bologna, Via Massarenti, 9 - 40138, Bologna, Italy.
Drugs
|August 30, 2025
概括
阿尔多合成酶抑制剂 (ASIs) 通过降低血压来治疗耐药高血压 (RHT),尤其是在阿尔多水平高的患者中. 基于个体因素的个性化治疗可能会改善RHT的结果.
科学领域:
- 药理学
- 肝脏病学
- 心脏病学
背景情况:
- 抗性高血压 (RHT) 是一种复杂的疾病,有多种原因,包括高阿尔多斯特隆症.
- 在某一小组患者中,阿尔多水平的升高对RHT的病理生理学有显著影响.
研究的目的:
- 系统地审查阿尔多合成酶抑制剂 (ASI) 的药理学特性.
- 评估ASI在治疗RHT方面的治疗潜力.
主要方法:
- 一个系统的文献搜索确定了对ASIs的临床试验和药理学研究.
- 研究的关键药物包括巴克斯德罗斯塔特,德克斯德罗斯塔特,洛伦德罗斯塔特,LY3045697和奥西洛斯塔特.
主要成果:
- 在办公室和24小时门诊血压方面,ASI显著降低.
- 特别是在阿尔多水平升高的患者中观察到有效性,证实了阿尔多在RHT中的作用.
- 具有不同的代谢途径,选择性特征和药物动力学特征.
结论:
- 阿尔多合成酶抑制剂代表了RHT的潜在治疗途径.
- 考虑功能,摄入量和并发症的个性化治疗策略对于优化RHT患者的ASI疗效和耐受性至关重要.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Antihypertensive Drugs: Angiotensin II Receptor Blockers
911
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
911
Antihypertensive Drugs: Potassium-Sparing Diuretics
751
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
751
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483


